Spinal Muscular Atrophy (SMA) Treatment Market Size, Share & Industry Analysis, By Product (Nusinersen and Onasemnogen Abeparvovec), By Disease Type (Type 1 SMA, Type 2 SMA and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), and Regional Forecast, 2019-2026 (Includes COVID-19 Business Impact)

                                          
We have updated Spinal Muscular Atrophy Treatment Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Spinal Muscular Atrophy Treatment market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Spinal Muscular Atrophy Treatment market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Spinal Muscular Atrophy Treatment Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Spinal Muscular Atrophy Treatment Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Spinal Muscular Atrophy Treatment Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

Biogen and Novartis AG focuses on introduction of advanced products to gain strategic position across the globe
Biogen and Novartis AG accounted for the complete market share in 2018, owing to their two main products for the treatment of spinal muscular atrophy. Spinraza (Nusinersen) by Biogen and Zolgensma (Onasemnogene abeparvovec) by Novartis are the only two products approved for the treatment of this disorder. Hence, these two companies hold complete dominance in terms of the market share. The other companies such as Genentech, Inc. (F. Hoffmann-La Roche Ltd) and Astellas Pharma hold key pipeline candidates, some of which are in the advanced stages of clinical trials.

LIST OF KEY COMPANIES PROFILED:

  
Biogen
  
Novartis AG
  
Genentech, Inc./ F. Hoffmann-La Roche Ltd
  
Astellas Pharma Inc.
  
Genzyme Corporation
  
Others

KEY INDUSTRY DEVELOPMENTS:

May 2019 - Zolgensma (onasemnogene abeparvovec-xioi) by Novartis AG received the approval from the U.S. FDA for the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)

December 2016 -The U.S. FDA approved the first-ever drug for spinal muscular atrophy called Spinraza (Nusinersen) from Biogen

REPORT COVERAGE

An Infographic Representation of Spinal Muscular Atrophy Treatment Market

View Full Infographic

To get information on various segments, share your queries with us

The report offers qualitative and quantitative insights on SMA treatment products and the detailed analysis of market size & growth rate for all possible segments in the market. Along with this, the report provides an elaborative analysis of market dynamics, emerging trends, and competitive landscape. Key insights offered in the report are the prevalence of spinal muscular atrophy for key countries, key industry developments, pipeline analysis, new product launches, reimbursement policies, regulatory scenario, and key industry trends.

Report Scope & Segmentation

 Segmentation

By Product

  
Nusinersen
  
Onasemnogen Abeparvovec

By Disease Type

  
Type 1 SMA
  
Type 2 SMA
  
Others

By Distribution Channel

  
Hospital Pharmacies
  
Retail Pharmacies
  
Others

By Geography

  
North America (U.S. and Canada)
  
Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
  
Asia Pacific (Japan, China, India, Australia, and Rest of Asia Pacific)
  
Rest of the World